Document Detail

Elevated tryptase levels selectively cluster in myeloid neoplasms: a novel diagnostic approach and screen marker in clinical haematology.
MedLine Citation:
PMID:  19522836     Owner:  NLM     Status:  In-Process    
BACKGROUND: Recent data suggest that tryptase, a mast cell enzyme, is expressed in neoplastic cells in myeloid leukaemias. In several of these patients, increased serum tryptase levels are detectable. MATERIALS AND METHODS: We have determined serum tryptase levels in 914 patients with haematological malignancies, including myeloproliferative disorders (n = 156), myelodysplastic syndromes (MDS, n = 241), acute myeloid leukaemia (AML, n = 317), systemic mastocytosis (SM, n = 81), non-Hodgkin's lymphoma (n = 59) and acute lymphoblastic leukaemia (n = 26). Moreover, tryptase was measured in 136 patients with non-neoplastic haematological disorders, 102 with non-haematological disorders and 164 healthy subjects. RESULTS: In healthy subjects, the median serum tryptase was 5.2 ng mL(-1). Elevated serum tryptase levels were found to cluster in myeloid neoplasm, whereas almost all patients with lymphoid neoplasms exhibited normal tryptase. Among myeloid neoplasms, elevated tryptase levels (> 15 ng mL(-1)) were recorded in > 90% of patients with SM, 38% with AML, 34% with CML and 25% with MDS. The highest tryptase levels, often > 1000 ng mL(-1), were found in advanced SM and core-binding-factor leukaemias. In most patients with non-neoplastic haematological disorders and non-haematological disorders analysed in our study, tryptase levels were normal, the exception being a few patients with end-stage kidney disease and helminth infections, in whom a slightly elevated tryptase was found. CONCLUSIONS: In summary, tryptase is a new diagnostic marker of myeloid neoplasms and a useful test in clinical haematology.
W R Sperr; A El-Samahi; M Kundi; M Girschikofsky; S Winkler; D Lutz; G Endler; H Rumpold; H Agis; C Sillaber; U Jäger; P Valent
Related Documents :
4043176 - Serum sialyltransferase and fucosyltransferase activities in patients with multiple mye...
20558926 - Evaluating the validity of serum neopterin and chitotriosidase levels in follow-up bruc...
19341456 - Increased expression levels of the pvcrt-o and pvmdr1 genes in a patient with severe pl...
9441116 - Clinical evaluation of serum type iv collagen 7s in idiopathic pulmonary fibrosis.
617596 - Supraclavicular and carotid bruits in hemodialysis patients.
8504796 - Steady state pharmacokinetics of conventional versus controlled-release carbamazepine i...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2009-06-12
Journal Detail:
Title:  European journal of clinical investigation     Volume:  39     ISSN:  1365-2362     ISO Abbreviation:  Eur. J. Clin. Invest.     Publication Date:  2009 Oct 
Date Detail:
Created Date:  2009-09-23     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0245331     Medline TA:  Eur J Clin Invest     Country:  England    
Other Details:
Languages:  eng     Pagination:  914-23     Citation Subset:  IM    
Medical University of Vienna, A-1090 Vienna, Austria.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Effects of AT1- and beta-adrenergic receptor antagonists on TGF-beta1-induced fibrosis in transgenic...
Next Document:  Renal artery stenosis predicts adverse cardiovascular and renal outcome in patients with peripheral ...